Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEVODOPA & BENSERAZIDE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N04B, N04BA) — coverage varies; not interchangeable

  • Carbidopa + levodopa (Sinemet CR): general benefit, Limited Use, Not a benefit
  • Carbidopa + entacapone + levodopa (Stalevo): limited Use 367
  • Amantadine (Symmetrel): general benefit, Not a benefit
  • Bromocriptine (Parlodel): general benefit, Not a benefit
  • Ropinirole (ReQuip): general benefit, Not a benefit
  • Selegiline (Eldepryl): general benefit, Not a benefit

Prolopa 50-12.5 · DIN 00522597 · 50mg & 12.5mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Prolopa 50-12.5 · DIN 00522597 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 1981-12-31 · brand PROLOPA CAP 50-12.5 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Capsule · route Oral · ingredients BENSERAZIDE (BENSERAZIDE HYDROCHLORIDE) 12.5 MG, LEVODOPA 50 MG · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Prolopa 50-12.5: Formulary list price $0.3508/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3508 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4459 · Verify on the e-Formulary ↗ (DIN 00522597)

Source record
DIN 00522597: Prolopa 50-12.5 Raw flags: sec3=Y Item: 920000037; group id 929; item number 2214; lccId None; manufacturer id HLR Source form: Cap; strength: 50mg & 12.5mg Recorded listing: General benefit Source prices (unrounded): $0.3508; ministry $0.3508 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00522597 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4459
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522597
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Prolopa 100-25 · DIN 00386464 · 100mg & 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Prolopa 100-25 · DIN 00386464 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 1977-12-31 · brand PROLOPA CAP 100-25 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Capsule · route Oral · ingredients LEVODOPA 100 MG, BENSERAZIDE (BENSERAZIDE HYDROCHLORIDE) 25 MG · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Prolopa 100-25: Formulary list price $0.5777/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5777 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2723 · Verify on the e-Formulary ↗ (DIN 00386464)

Source record
DIN 00386464: Prolopa 100-25 Raw flags: sec3=Y Item: 920000027; group id 929; item number 2215; lccId None; manufacturer id HLR Source form: Cap; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.5777; ministry $0.5777 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00386464 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2723
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00386464
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Prolopa 200-50 · DIN 00386472 · 200mg & 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Prolopa 200-50 · DIN 00386472 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 1977-12-31 · brand PROLOPA CAP 200-50 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Capsule · route Oral · ingredients LEVODOPA 200 MG, BENSERAZIDE (BENSERAZIDE HYDROCHLORIDE) 50 MG · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Prolopa 200-50: Formulary list price $0.9699/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9699 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2724 · Verify on the e-Formulary ↗ (DIN 00386472)

Source record
DIN 00386472: Prolopa 200-50 Raw flags: sec3=Y Item: 920000026; group id 929; item number 2216; lccId None; manufacturer id HLR Source form: Cap; strength: 200mg & 50mg Recorded listing: General benefit Source prices (unrounded): $0.9699; ministry $0.9699 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00386472 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2724
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00386472
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults > 25 years of age PROLOPA (levodopa and benserazide capsules) is indicated for the treatment of Parkinson’s disease with the exception of drug-induced parkinsonism. The administration of PROLOPA is associated with amelioration of the symptoms of Parkinson’s disease with the advantage that combined therapy significantly diminishes the incidence of the levodopa-induced peripheral side-effects of nausea, vomiting and possibly cardiac arrhythmias. This results in an advantage for those patients who previously were unable to tolerate an optimal daily dosage of levodopa. Improved gastrointestinal tolerance also provides for a more rapid induction of therapy, e.g., optimum dosage can in most cases be achieved within two to three weeks. However, combined therapy with levodopa and benserazide increases the incidence of centrally mediated abnormal movements earlier in therapy and can lead to an earlier appearance of oscillations in performance. Thus, when combined therapy with levodopa and benserazide is instituted it is important to strive at using and maintaining a dosage regimen which balances efficacy with freedom from dyskinesias. Despite the dra… https://pdf.hres.ca/dpd_pm/00052550.PDF PM date: August 2, 2019 Source product: PROLOPA CAP 100-25; DIN 00386464; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.